Search

Corvus Pharmaceuticals Inc

Gesloten

12.36 -2.6

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.22

Max

12.8

Belangrijke statistieken

By Trading Economics

Inkomsten

-4.3M

-18M

EPS

-0.19

Werknemers

37

EBITDA

-5.3M

-17M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+141.21% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-21M

1.1B

Vorige openingsprijs

14.96

Vorige sluitingsprijs

12.36

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

17 sep 2026, 23:56 UTC

Targa Resources Corp is trading modestly higher in after-market hours, recovering from an early decline and reaching a high near the session's end.

17 sep 2026, 23:56 UTC

Correlated Moves

Synaptics Inc declined during after-market hours, moving lower alongside the Nasdaq 100 Index amid positive economic data, including a drop in jobless claims.

17 sep 2026, 23:56 UTC

TransUnion is trading modestly higher in after-market hours, despite earlier gains settling and the price remaining below its 20-day moving average.

17 sep 2026, 23:56 UTC

Event
News

Rexford Industrial Realty completed a $1.2 billion sale of a 22-property portfolio to EQT Real Estate, with shares slightly declining in after-market trading.

17 sep 2026, 23:56 UTC

Correlated Moves

Saia Inc's shares traded roughly flat during after-market hours, remaining below the 20-day moving average and near the lower end of its one-month range.

17 sep 2026, 23:56 UTC

Fidelity National Information Services Inc is trading modestly higher in after-market hours following four consecutive sessions of losses, amid positive economic indicators.

17 sep 2026, 23:52 UTC

Pinterest Inc is trading higher in after-market hours, continuing a trend of higher daily closes since Thursday's close, despite recent divergence from upward momentum.

17 sep 2026, 23:51 UTC

Organon & Co. is experiencing a modest decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month trading range.

17 sep 2026, 23:51 UTC

Hawkins Inc is advancing in after-market trading, reaching its highest cumulative return of the day amid a one-month trading range.

17 sep 2026, 23:51 UTC

Turning Point Brands Inc has advanced in after-market trading, recovering sharply from a low immediately following Thursday's close, contributing to an overall higher position.

17 sep 2026, 23:51 UTC

TransDigm Group Inc is seeing modest gains in after-market trading, recovering from earlier lows but remains below its 20-day moving average.

17 sep 2026, 23:51 UTC

American Electric Power Company Inc is trading modestly lower in after-market hours, continuing a decline from Thursday's close and remaining below its 20-day moving average.

17 sep 2026, 23:51 UTC

Alliant Energy Corp is trading modestly higher in after-market hours, showing stability with slight upward movement and fluctuations within a narrow range.

17 sep 2026, 23:51 UTC

Correlated Moves

BHP Group Ltd is advancing in after-market trading, reflecting a notable upward movement since Thursday's close, despite remaining below its 20-day moving average.

17 sep 2026, 23:51 UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

17 sep 2026, 23:51 UTC

Chicago Fed National Activity Index Release on September 21, 2026: Market Awaits Insights Amid Cautious Optimism and Inflation Concerns.

17 sep 2026, 23:51 UTC

Mortgage Rates Hit 6.97%, Highest Since May 2025, as Market Sentiment Wanes Ahead of Upcoming MBA Release

17 sep 2026, 23:51 UTC

Japan's Core Inflation Rate for August at 1.7% Falls Short of Expectations, Raising Concerns Over Economic Stability and Monetary Policy Effectiveness

17 sep 2026, 23:51 UTC

Japan's August Inflation Rate at 1.9% Falls Short of Expectations, Raising Concerns for Monetary Policy Adjustments Amidst Weak Demand

17 sep 2026, 23:51 UTC

Correlated Moves

Las Vegas Sands Corp is trading modestly higher in after-market hours, following a pullback earlier in the session, aligning with Wynn Resorts Ltd's gains.

17 sep 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a volatile session.

17 sep 2026, 23:51 UTC

FedEx Corp is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month trading range.

17 sep 2026, 23:51 UTC

ICU Medical Inc declined in after-market trading, reaching its lowest point shortly after the market closed and remaining below its 20-day moving average.

17 sep 2026, 23:51 UTC

In after-market trading, Dave and Buster's Entertainment, Inc. is advancing, reflecting a notable increase since Thursday's close, despite being below its 20-day moving average.

17 sep 2026, 23:51 UTC

SLB NV is trading modestly higher in after-market hours, following fluctuations that led to a cumulative return of 0.89% shortly after the market closed.

17 sep 2026, 23:51 UTC

Correlated Moves

Cardinal Health Inc is trading modestly higher in after-market hours, following a slight uptick in Cencora Inc, which is recovering from recent declines.

17 sep 2026, 23:51 UTC

Bath & Body Works Inc. is declining in after-market trading, currently near its lowest point of the day and below its 20-day moving average.

17 sep 2026, 23:46 UTC

Ecolab Inc is trading modestly higher in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

17 sep 2026, 23:46 UTC

Daqo New Energy Corp is trading higher in after-market hours, closing at its highest point despite challenges, as U.S. jobless claims fell to 196k.

17 sep 2026, 23:46 UTC

N-Able Inc gained in after-market trading, advancing since Thursday's close and stabilizing above its 20-day moving average near the upper end of its one-month range.

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

141.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.5 USD  141.21%

Hoogste 33 USD

Laagste 27 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.